UBC has provided patient access and support services for more than 50 oncology products, including 6 of the top-selling cancer medications in the past three years.
UBC has provided clinical development and safety services for more than 75 oncology projects, touching nearly 25,000 subjects and over 3,100 sites.
Our comprehensive services are backed by some of the industry’s most distinguished oncology professionals. Our teams rely on these individuals for up-to-date expert oncology guidance.
Annette Stemhagen, DrPH, FISPE
Safety, Epidemiology, Registries & Risk Management
Dr. Stemhagen provides strategic consultative services to pharmaceutical and biotechnology clients in epidemiology, safety surveillance, and risk management. Dr. Stemhagen has extensive oncology experience, having served as a principal investigator and collaborator on multiple national cancer studies through the National Cancer Institute, FDA, and EPA. As part of the National Cancer Institute’s Surveillance, Epidemiology, and End Results Program (SEER), Dr. Stemhagen helped establish the New Jersey State Cancer Registry, which collects data on all cancer cases diagnosed and/or treated in the state.
Don A. Gabriel, MD, PhD
Medical Oncology & Scientific Strategy
Dr. Gabriel is a nationally recognized oncology hematologist in stem cell transplant for liquid tumors and selected solid tumors. As a consultant, Dr. Gabriel directs UBC’s oncology program design and development. He is responsible for developing strategic and fully integrated pre- and post-marketing oncology programs for our manufacturer clients.
UBC as Your Oncology Partner
Oncology manufacturers choose UBC because of our depth and breadth of oncology expertise. We are the only organization that can support your product’s entire lifecycle. Through clinical development, risk management strategies, and patient access and support, UBC has the streamlined, comprehensive solutions that your oncology product needs.
From Development & Safety...
UBC’s Clinical Development and Late Stage Research teams collaborate with manufacturer sponsors to help ensure conclusive study results and meet global regulatory submissions requirements.
Our expertise in the design, conduct, and analysis of full-service oncology clinical development programs makes certain that safety and efficacy evidence needs are satisfied for regulatory review.
Because of the toxicities and adverse events that accompany therapy, oncology treatments are closely regulated. UBC has global expertise in managing risks associated with cancer treatments before, during, and after launch. We also have a team of skilled safety scientists, physicians, and medical writers who perform pharmacovigilance activities, and who recognize the unique challenges associated with oncology therapies.
Our Clinical & Safety Experience Includes:
Acute Myelogenous Leukemia • Chronic Myelogenous Leukemia • Myelofibrosis • Myelodysplastic Syndromes • Peripheral T-Cell Lymphoma
Breast Cancer • Colorectal Cancer • Colorectal Liver Metastases • Exploratory Tumor Types • Gastrointestinal Stromal Tumor • Lung Adenocarcinoma • Medullary Thyroid Cancer • Melanoma • Non-Small Cell Lung Cancer • Ovarian cancer • Pancreatic cancer • Pituitary Macroadenomas • Prostate Cancer • Renal Cell Cancer • Sarcoma • Small Cell Lung Cancer • Solid Tumor Malignancies
Anemia in Cancer • Anemia Caused by Chemotherapy in Usual Care • Breast Cancer Patients at Risk for Febrile Neutropenia • Cancer • Canine Cancer • Prevention of Skeletal Events in Oncology Patients • Stomatitis in Advanced Breast Cancer
How does UBC solve our oncology manufacturers’ most pressing pain points? Click below to find out.
...to Patient Access
Our oncology support services are tailored by disease state, product, and patient needs. UBC’s reimbursement services build brand loyalty with oncology patients, caregivers, and healthcare professionals by successfully addressing issues that stand in the way of patient access. We can design and manage a Patient Assistance Program (PAP) to provide access for uninsured and underinsured patients.
UBC also offers robust adherence support programs designed to enhance patients’ therapeutic journeys. Our nurses are experts in oncology and perform a variety of functions, including telephonic support and patient education through our Clinical Support Centers, Site of Care administration, injection training, and administration of complex specialty products.
Watch the video below to learn how one of our oncology support programs provided personalized care to patients through their entire therapeutic journey — while saving the manufacturer money:
Our patient access and support teams have experience in:
Breast Cancer • Colorectal Cancer • Esophageal Cancer • Gastrointestinal Stromal Tumor • Neuroendocrine Tumors • Non-Small Cell Lung Cancer • Ovarian Cancer • Prostate Cancer • Renal Cell Cancer • Thyroid Cancer
Acute Lymphocytic Leukemia • Acute Myelogenous Leukemia • Chronic Lymphocytic Leukemia • Chronic Myelogenous Leukemia • Cutaneous T-Cell Lymphoma • Hodgkin's Lymphoma • Lymphomatous Meningitis • Myelodysplastic Syndrome
Cancer • Chemotherapy-Induced Nausea and Vomiting • Tuberous Sclerosis Complex • Chemotherapy Induced Hypercalcemia
We know that one size does not fit all when it comes to treating cancer. Imagine the value of knowing how a patient will react to an oncology therapy well before the clinical trial even begins. Pharmacogenomics enables us to predict how an individual’s genes will affect his or her response to specific therapies. The role of pharmacogenomics is particularly significant to oncology, as tailored therapies maximize effectiveness and minimize adverse events. With experience in advanced pharmacogenomics recruitment strategies, UBC helps manufacturers develop targeted, safe, and effective medications.
Pharmacogenomics: One Size Does Not Fit All
Pharmacogenomics is Changing Oncology: 5 Things You Need to Know Now